» Articles » PMID: 21775832

Memantine and Catatonia: a Case Report and Literature Review

Overview
Specialty Psychiatry
Date 2011 Jul 22
PMID 21775832
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Catatonia is a movement disorder with various possible etiologies. The majority of cases are associated with an underlying mood or psychotic disorder, while others are caused by medical conditions. Currently, benzodiazepines are the first-line psychopharmacologic agents in the treatment of catatonia. However, several cases have been reported in which treatment with memantine proved to be effective. We present the case of a 92-year-old female with major depressive disorder and associated catatonic symptoms. In this case, the patient's symptoms remitted quickly after the initiation of memantine. We review the possible causes of catatonia and pharmacologic treatments for the condition and highlight the possible benefits of N-methylD-aspartic acid receptor antagonists such as memantine in the treatment of catatonia.

Citing Articles

The Clinical Course of a Severe Case of Malignant Catatonia.

Gopal K, Liengswangwong R, Ramaraj S, Howard J, Byrd J Cureus. 2024; 16(4):e58142.

PMID: 38741865 PMC: 11088969. DOI: 10.7759/cureus.58142.


Oral and Intranasal Ketamine Use in Treatment-Resistant Catatonia: A Clinical Case Report.

Gregor E, Zheng W Am J Case Rep. 2023; 24:e939530.

PMID: 37095688 PMC: 10151068. DOI: 10.12659/AJCR.939530.


Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology.

Rogers J, Oldham M, Fricchione G, Northoff G, Wilson J, Mann S J Psychopharmacol. 2023; 37(4):327-369.

PMID: 37039129 PMC: 10101189. DOI: 10.1177/02698811231158232.


Molecular and cellular mechanisms leading to catatonia: an integrative approach from clinical and preclinical evidence.

Ariza-Salamanca D, Corrales-Hernandez M, Pachon-Londono M, Hernandez-Duarte I Front Mol Neurosci. 2022; 15:993671.

PMID: 36245923 PMC: 9558725. DOI: 10.3389/fnmol.2022.993671.


Is Memantine Effective as an NMDA-Receptor Antagonist in Adjunctive Therapy for Schizophrenia?.

Kikuchi T Biomolecules. 2020; 10(8).

PMID: 32751985 PMC: 7466074. DOI: 10.3390/biom10081134.